UK markets open in 7 hours 3 minutes
  • NIKKEI 225

    28,401.79
    +277.51 (+0.99%)
     
  • HANG SENG

    24,383.32
    -46.48 (-0.19%)
     
  • CRUDE OIL

    84.42
    +0.60 (+0.72%)
     
  • GOLD FUTURES

    1,815.00
    -1.50 (-0.08%)
     
  • DOW

    35,911.81
    -201.79 (-0.56%)
     
  • BTC-GBP

    31,464.72
    -199.63 (-0.63%)
     
  • CMC Crypto 200

    1,037.16
    +11.43 (+1.11%)
     
  • ^IXIC

    14,893.75
    +86.95 (+0.59%)
     
  • ^FTAS

    4,256.59
    -16.64 (-0.39%)
     

China Nifedipine Market Investigation Report 2021-2025

·4-min read

Dublin, Dec. 31, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Nifedipine Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

According to the analyst's market research, the sales value of Nifedipine in the Chinese market increased year by year from 2016 to 2019. In 2020, due to the impact of Covid-19 on the overall medical diagnosis and treatment services, the sales value of Nifedipine in the Chinese market fell to CNY730 million, and the CAGR of Nifedipine from 2016 to 2020 was 4.42%.

The analyst expects that with the relief of Covid-19, the sales value of Nifedipine in the Chinese market will have a restorative growth from 2021 to 2025. In addition, in recent years, nearly 20 million people worldwide died of cardiovascular and cerebrovascular diseases caused by hypertension and coronary heart disease each year.

Nifedipine is a dihydropyridine calcium channel blocker, which is mainly used to bind to L-type calcium channels. Nifedipine is mainly used to treat chronic stable angina pectoris, vasospasm angina pectoris (angina pectoris, variant angina pectoris) and essential hypertension. Nifedipine was developed by Bayer AG, and Bayer AG's Nifedipine is traded under the name ADALAT. By 2020, there are several manufacturers in China's Nifedipine market, among which Bayer AG has the highest market share in sales value.

An estimated 300 million patients live with high blood pressure in China. As ageing of population in China becomes increasingly severe, the number and prevalence of patients are increasing year by year. Therefore, there is an increasing trend in sales volume of Nifedipine for the treatment of angina and hypertension.

At the same time, compared with similar drugs, Nifedipine has longer action time, fewer doses, more stable blood concentrations, and less toxic and side effects. Based on these advantages, the sales volume and sales value of Nifedipine in the Chinese market will continue to grow from 2021 to 2025.

Topics Covered:

  • The impact of COVID-19 on China's Nifedipine market

  • Sales value of China's Nifedipine 2016-2020

  • Competitive landscape of China's Nifedipine market

  • Prices of Nifedipine in China

  • Prices of Nifedipine in China by regions and manufacturers

  • Analysis on factors affecting the development of China's Nifedipine market

  • Prospect of China's Nifedipine market from 2021 to 2025

Key Topics Covered:

1 Relevant Concepts of Nifedipine
1.1 Indications for Nifedipine
1.2 Development of Nifedipine in China
1.3 Governmental Approval of Nifedipine in China
1.4 The Impact of COVID-19 on Nifedipine sales in China

2 Sales of Nifedipine in China, 2016-2020
2.1 Sales Value of Nifedipine
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Nifedipine
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Nifedipine by Dosage Form in China, 2016-2020
2.3.1 Controlled Release Tablets
2.3.2 Tablets
2.3.3 Sustained Release Tablets
2.3.4 Soft Capsules

3 Analysis of Major Nifedipine Manufacturers in China, 2016-2020
3.1 Analysis of Market Share of Major Nifedipine Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Bayer AG
3.2.1 Enterprise Profile
3.2.2 Sales of ADALAT (Bayer AG's Nifedipine) in China
3.3 Shanghai Shyndec Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Xinran (Shanghai Shyndec Pharmaceutical Co., Ltd.'s Nifedipine) in China
3.4 Qingdao Huanghai Pharmaceutical Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Maikaofen (Qingdao Huanghai Pharmaceutical Co., Ltd.'s Nifedipine) in China
3.5 Beijing Honglin Pharmaceutical Co., Ltd.
3.5.1 Enterprise Profile
3.5.2 Sales of Nifuda (Beijing Honglin Pharmaceutical Co., Ltd.'s Nifedipine) in China
3.6 Yangtze River Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd.
3.6.1 Enterprise Profile
3.6.2 Sales of Shansu (Yangtze River Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd.'s Nifedipine) in China

4 Prices of Nifedipine for Different Manufacturers in China, 2020-2021
4.1 Bayer AG (ADALAT)
4.2 Shanghai Shyndec Pharmaceutical Co., Ltd. (Xinran)
4.3 Qingdao Huanghai Pharmaceutical Co., Ltd. (Maikaofen)
4.4 Beijing Honglin Pharmaceutical Co., Ltd. (Nifuda)
4.5 Yangtze River Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd. (Shansu)

5 Prospect of Chinese Nifedipine Market, 2021-2025
5.1 Influential Factors of Chinese Nifedipine Market Development
5.1.1 The Impact of COVID-19 on Chinese Nifedipine Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

Companies Mentioned

  • Bayer AG (ADALAT)

  • Shanghai Shyndec Pharmaceutical Co., Ltd. (Xinran)

  • Qingdao Huanghai Pharmaceutical Co., Ltd. (Maikaofen)

  • Beijing Honglin Pharmaceutical Co., Ltd. (Nifuda)

  • Yangtze River Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd.(Shansu)

For more information about this report visit https://www.researchandmarkets.com/r/ephsng

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting